The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study

William H Herman, William H Herman

Abstract

Background: The Diabetes Prevention Program (DPP) was a randomized, controlled clinical trial. It demonstrated that among high-risk individuals with impaired glucose tolerance, diabetes incidence was reduced by 58 % with lifestyle intervention and 31 % with metformin compared to placebo. During the Diabetes Prevention Program Outcomes Study (DPPOS), all DPP participants were unmasked to their treatment assignments, the original lifestyle intervention group was offered additional lifestyle support, the metformin group continued metformin, and all three groups were offered a group-implemented lifestyle intervention. Over the 10 years of combined DPP/DPPOS follow-up, diabetes incidence was reduced by 34 % in the lifestyle group and 18 % in the metformin group compared to placebo. The purpose of this article is to review and synthesize analyses published by the DPP/DPPOS Research Group that have described the cost-effectiveness of diabetes prevention.

Methods: We describe the resource utilization and costs of the DPP and DPPOS interventions, the costs of non-intervention-related medical care, the impact of the interventions on diabetes progression and quality-of-life, and the cost-effectiveness of the interventions from health system and societal perspectives. Cost-effectiveness analyses were performed with a 3-year time horizon using DPP data, a lifetime time horizon that simulated 3-year DPP data, and a 10-year time horizon using combined DPP/DPPOS data.

Results: Although more expensive than the placebo intervention, the greater costs of the lifestyle and metformin interventions were offset by reductions in the costs of nonintervention-related medical care. Every year after randomization, quality-of-life was better for participants in the lifestyle intervention compared to those in the metformin or placebo intervention. In both the simulated lifetime analysis and the 10-year within trial economic analysis, lifestyle and metformin were extremely cost-effective (that is, improved outcomes at a low incremental cost) or even cost-saving (that is, improved outcomes and reduced total costs) compared to the placebo intervention.

Conclusions: The implementation of diabetes prevention programs in high-risk individuals will result in important health benefits and represents a good value for money.

Trial registration: NCT00004992 (DPP) and NCT00038727 (DPPOS).

Keywords: Cost; Cost-utility; Quality-of-life.

Figures

Fig. 1
Fig. 1
Simulated cumulative incidence of diabetes among adults with impaired glucose tolerance over a lifetime
Fig. 2
Fig. 2
Observed cumulative incidence of diabetes among adults with impaired glucose tolerance over the combined 10-years of DPP/DPPOS

References

    1. The Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. N Engl J Med. 2002;346:393–403. doi: 10.1056/NEJMoa012512.
    1. Diabetes Prevention Program Research Group The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165–71. doi: 10.2337/diacare.25.12.2165.
    1. Diabetes Prevention Program Research Group The diabetes prevention program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623–34. doi: 10.2337/diacare.22.4.623.
    1. The Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86. doi: 10.1016/S0140-6736(09)61457-4.
    1. The Diabetes Prevention Program Research Group Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36–47. doi: 10.2337/diacare.26.1.36.
    1. The Diabetes Prevention Program Research Group Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518–23. doi: 10.2337/diacare.26.9.2518.
    1. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32. doi: 10.7326/0003-4819-142-5-200503010-00007.
    1. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304–21. doi: 10.1016/S0149-2918(04)90029-X.
    1. Caro JJ, Getsios D, Caro I, Klittich WS, O’Brien JA. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diab Med. 2004;21:1229–36. doi: 10.1111/j.1464-5491.2004.01330.x.
    1. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64. doi: 10.7326/0003-4819-143-4-200508160-00006.
    1. The Diabetes Prevention Program Research Group The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723–30. doi: 10.2337/dc11-1468.
    1. Hoerger TJ, Segel JE, Zhang P, Sorensen SW: Validation of the CDC-RTI diabetes cost-effectiveness model. RTI Press publication No. MR-0013-0909. Research Triangle Park, N.C: RTI International, 2009.
    1. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300–4. doi: 10.2337/diacare.26.8.2300.
    1. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25:2238–43. doi: 10.2337/diacare.25.12.2238.
    1. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358:661–3. doi: 10.1056/NEJMp0708558.
    1. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516–22. doi: 10.1056/NEJMsb050564.
    1. American Diabetes Association Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46. doi: 10.2337/dc12-2625.
    1. Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, Crosson JC, Herman WH. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19:421–30.
    1. Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, Diabetes Prevention Program Research Group Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet. 2013;113:1455–64. doi: 10.1016/j.jand.2013.07.003.
    1. Venditti EM, Wylie-Rosett J, Delahanty LM, Mele L, Hoskin MA, Edelstein SL, Diabetes Prevention Program Research Group Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act. 2014;11:16. doi: 10.1186/1479-5868-11-16.
    1. Jaacks LM, Ma Y, Davis N, Delahanty LM, Mayer-Davis EJ, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, Diabetes Prevention Program Research Group Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabet Med. 2014;31:1631–42. doi: 10.1111/dme.12500.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel